Date: 2015-05-27
Type of information: Fundraising
Company: Fate Therapeutics (USA - CA)
Investors:
Amount: $32 million
Funding type: fundraising
Planned used: Fate Therapeutics, a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, intends to use the net proceeds from the offering for clinical development and research activities, working capital and other general corporate purposes.
Others: * On May 27, 2015, Fate Therapeutics, a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, announced the closing of an underwritten public offering of 6,900,000 shares of its common stock, which included 900,000 shares that were issued pursuant to the full exercise of the underwriters\' option to purchase additional shares, at a public offering price of $5.00 per share. Net proceeds from this offering were approximately $32 million, after deducting underwriting discounts and commissions and estimated offering expenses. * On May 20, 2015, Fate Therapeutics announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $5.00 per share, before underwriting discounts, for an aggregate offering of $30 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected to be approximately $27.7 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters\' option. * On May 18, 2015, Fate Therapeutics announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. Fate Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock.
Leerink Partners LLC and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Wedbush PacGrow and H.C. Wainwright & Co., LLC acted as co-managers.
Therapeutic area: Cancer - Oncology - Rare diseases - Genetic diseases - Hematological diseases
